[Dependence of neuropeptide physiological effects on a route of administration]

Ross Fiziol Zh Im I M Sechenova. 2001 Nov;87(11):1493-501.
[Article in Russian]

Abstract

Following intranasal administration, the peptides' effects could remain either the same as following an invasive administration (ACTH4-10) which is important for clinical application, or enhanced and prolonged (demorphin and argynilvasopressin analogue), or modified (beta-casomorphin-7). Techniques of improvement of the peptides' regulatory efficacy through protection against the protease action, are discussed. Peptide protection by introducing D-aminoacid's isomers into its molecule or addition of proline-rich sequences were compared. The latter technique seems to be more effective.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Intranasal
  • Adrenocorticotropic Hormone / administration & dosage
  • Adrenocorticotropic Hormone / analogs & derivatives
  • Adrenocorticotropic Hormone / pharmacology
  • Animals
  • Arginine Vasopressin / administration & dosage
  • Arginine Vasopressin / analogs & derivatives
  • Arginine Vasopressin / pharmacology
  • Avoidance Learning / drug effects
  • Behavior, Animal / drug effects
  • Endorphins / administration & dosage
  • Endorphins / pharmacology
  • Injections, Intraperitoneal
  • Male
  • Neuroprotective Agents / administration & dosage*
  • Neuroprotective Agents / pharmacology
  • Oligopeptides / administration & dosage*
  • Oligopeptides / pharmacology
  • Opioid Peptides
  • Pain Measurement
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology
  • Rats
  • Rats, Wistar

Substances

  • Endorphins
  • Neuroprotective Agents
  • Oligopeptides
  • Opioid Peptides
  • Peptide Fragments
  • Arginine Vasopressin
  • dermorphin
  • beta-casomorphin 7
  • ACTH (4-7), Pro-Gly-Pro-
  • Adrenocorticotropic Hormone